The identification of combinations for the CDK4 and CDK6 inhibitor, abemaciclib

被引：0
|
作者：
Gong Xueqian
Chio, Li-Chun
Webster, Yue
Lallena, Maria Jose
Boehnke, Karsten
Torres, Raquel
Iversen, Phil
De Dios, Alfonso
Smith, Ian
Reinhard, Christoph
Peng, Sheng-Bin
Dempsey, Jack
Burke, Teresa
Chen, Shih-Hsun
Stewart, Trent
Beckmann, Richard
Wu, Wenjuan
Buchanan, Sean G.
机构：
来源：
MOLECULAR CANCER RESEARCH | 2016年 / 14卷
关键词：
D O I：
10.1158/1557-3125.CELLCYCLE16-A07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Targeting prostate cancer with the CDK4 and CDK6 inhibitor abemaciclib
    Torres-Guzman, Raquel
    Baquero, Carmen
    Patricia Ganado, Maria
    Marugan, Carlos
    Bian, Huimin
    Zeng, Yi
    Rama, Ramon
    Du, Jian
    Jose Lallena, Maria
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [2] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    [J]. FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [3] The major human metabolites of abemaciclib are inhibitors of CDK4 and CDK6
    Burke, Teresa
    Torres, Raquel
    McNulty, Ann
    Dempsey, Jack
    Kolis, Stanley
    Kulanthaivel, Palaniappan
    Beckmann, Richard
    [J]. CANCER RESEARCH, 2016, 76
  • [4] Molecular features that determine the sensitivity of cancer cells to abemaciclib, an inhibitor of CDK4 and CDK6
    Gong, Xuegian
    Chio, Li -Chun
    Lallena, MaryJo
    Merzoug, Farhana
    Chu, Shaoyou
    Webster, Yue
    Dempsey, Jack
    Ma, Xiwen
    De Dios, Alfonso
    Beckman, Richard
    Buchanan, Sean G.
    [J]. CANCER RESEARCH, 2015, 75
  • [5] PALBOCICLIB Cyclin CDK4/CDK6 Inhibitor Oncolytic
    Haddley, K.
    [J]. DRUGS OF THE FUTURE, 2013, 38 (11) : 745 - 755
  • [6] Targeting CDK4 and CDK6 in cancer
    Shom Goel
    Johann S. Bergholz
    Jean J. Zhao
    [J]. Nature Reviews Cancer, 2022, 22 : 356 - 372
  • [7] Targeting CDK4 and CDK6 in cancer
    Goel, Shom
    Bergholz, Johann S.
    Zhao, Jean J.
    [J]. NATURE REVIEWS CANCER, 2022, 22 (06) : 356 - 372
  • [8] Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6
    Delach, Scott
    Caponigro, Giordano
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [9] Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
    Gong, Xueqian
    Litchfield, Lacey M.
    Webster, Yue
    Chio, Li-Chun
    Wong, Swee Seong
    Stewart, Trent R.
    Dowless, Michele
    Dempsey, Jack
    Zeng, Yi
    Torres, Raquel
    Boehnke, Karsten
    Mur, Cecilia
    Marugan, Carlos
    Baquero, Carmen
    Yu, Chunping
    Bray, Steven M.
    Wulur, Isabella H.
    Bi, Chen
    Chu, Shaoyou
    Qian, Hui-Rong
    Iversen, Philip W.
    Merzoug, Farhana F.
    Ye, Xiang S.
    Reinhard, Christoph
    De Dios, Alfonso
    Du, Jian
    Caldwell, Charles W.
    Jose Lallena, Maria
    Beckmann, Richard P.
    Buchanan, Sean G.
    [J]. CANCER CELL, 2017, 32 (06) : 761 - +
  • [10] The CDK4/CDK6 inhibitor abemaciclib inhibits transcriptional targets which facilitate growth in ER plus breast cancer cells
    McNulty, Ann M.
    Burke, Teresa
    Dempsey, Jack A.
    Marchal, Christophe C.
    Schade, Andrew E.
    Szpurka, Hadrian P.
    Dowless, Michele S.
    Stephens, Jennifer
    Stephens, Jennifer
    Edmondson, Denise
    Stayrook, Keith
    Caldwell, William C.
    Buchanan, Sean
    Merzoug, Farhana F.
    Beckmann, Richard P.
    [J]. MOLECULAR CANCER RESEARCH, 2016, 14
12345